Siemens (NYSE:SI) Healthineers said today it tapped former Abbott (NYSE:ABT) Vascular president Dr. Deepak Nath as its new laboratory diagnostics business president, taking over for Franz Walt who operated as president from 2014 to 2017.
Nath spent 10 years with Abbott, serving most recently as its vascular division president and as an executive officer of the company, and as president of the molecular diagnostics division prior to that.
“Siemens Healthineers seeks to benefit from market opportunities in the diagnostics market through the introduction of Atellica Solution. Deepak Nath’s exceptional leadership experience and deep industry knowledge will greatly benefit us as we look to expand the early success of Atellica Solution and drive wide adoption in the diagnostics market,” Siemens Healthineers COO Michael Reitermann said in a press release
The Chicago-based company said that its board of directors has initiated a search for a successor, which it hopes will be completed by the company’s fiscal third quarter.
“It has been an honor to lead this great company over the last eight years, and I am extremely proud of the value we have created together for patients, customers and shareholders. I want to thank each of our 10,000 employees around the world for their support and ongoing commitment to helping people get better care inside and outside the hospital. This is the right time for me personally, and for the company, to transition to the next generation of leadership. Hill-Rom is well positioned for future success with a strong team, solid foundation, and exciting growth prospects, and I look forward to working alongside our tremendous leadership team until we’ve successfully transitioned to my successor,” Greisch said in a prepared statement.
“On behalf of the Board, I would like to thank John for his invaluable leadership and significant contributions to Hill-Rom. Under his leadership, Hill-Rom has transformed its business portfolio, expanded globally and enhanced its position as a global medical device leader. John has directed Hill-Rom to record profitability, created significant shareholder value and positioned the company for a great future. Our company and leadership team have never been stronger, and we look forward to a seamless transition,” board chair Rolf Classon said in a press release.
Surefire Medical said this month it tapped former Novelion Therapeutics chief exec Mary Szela as its new prez and CEO, succeeding founder James Chomas who held the position of prez & CEO since 2009.
Former CEO Chomas will remain on the company’s board of directors and as an active member of the senior management, the Denver-based company said.
“Immune therapies are reshaping the battle against cancer. The innovative application of technology at Surefire positions the company to become a leading medical device provider in the treatment of cancer. Mary brings the leadership capabilities necessary to fulfill the full potential of what Surefire’s technology can do to transform cancer care on a global scale. Her proven commercial track record, coupled with her passion and commitment to patients, aligns with the company’s mission to better deliver quality of life for cancer patients. The brilliance of Jim Chomas is his ability to look at medical problems and solve them by creating technologies that help physicians successfully treat liver cancer. As the founder of Surefire, he built the company to where it is today and will continue to play an active role focused on innovations that overcome unsolved medical challenges. We’re grateful for all Jim does to advance oncology drug delivery and Surefire’s mission,” board chair Mats Wahlström said in a press relese.
Prior to joining Surefire, Szela held the corner office at Novelion Therapeutics where she oversaw a merger with Aegerion Pharma and QLT Therapeutics, the company said. She also acted as CEO at Melinta Therapeutics and held management positions at Abbott, including as president of its US pharmaceuticals business.
“As with millions of other people who have been directly or indirectly affected by cancer, I’m thrilled to be leading a company making a difference in treating the disease. The application of technology at Surefire is already making a difference, and guiding the company to expand its reach to patients is my primary goal. I’m fortunate to partner with Jim as a member of my staff along with the talented team at Surefire to advance technologies that can truly impact patient care,” Szela said in a prepared statement.
Cardiovascular Systems (Nasdaq: CSII) said last week it has appointed former Medtronic (NYSE:MDT) heart valve therapies GM Rhonda Robb as its new COO, replacing Kevin Kenny who is exiting the position at the end of this month.
During their time at Medtronic, Robb also held positions in the company’s coronary, peripheral and cardiac rhythm businesses.
“I am excited to have the opportunity to join CSI and I look forward to working with the team to improve the health of people with coronary and peripheral artery disease,” Robb said in prepared remarks.
“Rhonda is a dynamic and talented executive with extraordinary experience in driving innovation and growth in medical technology. She has the leadership ability, executional strengths and experience to further build CSI, and achieve our ambitious growth goals, as well as guide the expansion of the company’s peripheral and coronary franchises. As Chief Operating Officer, Kevin has made many contributions to the growth and success of CSI. We are grateful for his commitment to our mission and wish him well in his future endeavors,” prez & CEO Scott Ward said in a press release.
Prior to joining Irvine, Calif.-based Endologix, Morrow held the position of coronary division and marketing function leader for Abbott Vascular. He also held positions with Novartis (NYSE:NVS), Johnson & Johnson (NYSE:JNJ) and Align Technology (NSDQ:ALGN).
“We are very excited to welcome Greg to Endologix’s executive team. He is a proven marketing executive with a strong track record of growing medical device businesses in highly competitive and challenging environments and achieving breakthrough results. His experience will be invaluable in both strengthening our brand value proposition and maximizing the impact of our innovative new product pipeline,” Endologix CEO John McDermott said in a prepared statement.
“I am thrilled to have the opportunity to lead Endologix’s global marketing team. The company has built an impressive new product portfolio, and our marketing team’s goal is to effectively launch these new technologies, strengthen the brand, and provide excellent clinical outcomes for physicians and their patients,” Greg Morrow said in a press release.
- Neuromod Devices Limited names Lim as chief scientific officer
- Lohmann & Rauscher CCO Sebastian to step away
- Cook Group promotes Giles to federal & int’l gov’t affairs VP
- CHF Solutions taps Ephshteyn as ops & engineering VP
- Invetech names Kneen as cell therapy VP